Filtered By:
Condition: Heart Failure
Drug: Coumadin

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 289 results found since Jan 2013.

Preserve the Brain: Primary Goal in the Therapy of Atrial Fibrillation∗
Treatment of atrial fibrillation (AF) involves 3 major strategies: prevention of stroke, maintenance of sinus rhythm, and rate control . Stroke is the most dreaded complication of AF, and its prevention is key. Anticoagulation with warfarin and the newer agents dabigatran, rivaroxaban, and apixaban is highly effective in preventing strokes in patients with AF . However, defining the appropriate patient for anticoagulant therapy is not an exact science, and the stroke risk schema CHADS2 (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, previous Stroke/transient ischemic attack) and CHA2DS2-VASc (...
Source: Journal of the American College of Cardiology - May 17, 2013 Category: Cardiology Authors: Eric N. Prystowsky, Benzy J. Padanilam Tags: Heart Rhythm Disorders: Editorial Comment Source Type: research

Abstract 25: Predicting Outcomes among Patients with Heart Failure Receiving Anticoagulation with Warfarin Concurrent III Session A: Oral Abstract Presentations on EHS & Health IT
Conclusion: We developed a composite score for CHF severity which predicted both anticoagulation control and the rate of major hemorrhage among patients anticoagulated with warfarin. This study suggests that relatively easily observable characteristics can be used to risk-stratify patients with CHF who are receiving anticoagulation for AF.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Kim, E.-J., Rose, A. Tags: Concurrent III Session A: Oral Abstract Presentations on EHS & amp; Health IT Source Type: research

Abstract 217: How well does the CHADS2 Stroke Risk Score Predict Major Hemorrhage in Patients with Atrial Fibrillation? Poster Session II
Conclusions: Although some clinical markers of stroke risk such as those included in the CHADS2 risk score are also associated with increased hemorrhage risk, the CHADS2 risk score should not be used instead of a validated hemorrhage risk tool to estimate hemorrhage risk.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Quinn, G. R., Singer, D. E., Go, A. S., Chang, Y., Borowsky, L., Pomernacki, N., Udaltsova, N., Fang, M. C. Tags: Poster Session II Source Type: research

Upper limb arterial thromboembolism: a systematic review on incidence, risk factors, and prognosis, including a meta‐analysis of risk‐modifying drugs
ConclusionsAge, female sex, AF, hypertension, diabetes, myocardial infarction, heart failure and stroke are most common risk factors for thromboembolectomy of the upper limb. The availability of new OACs holds promise for reducing the risk of systemic thromboembolism, but specific data are still limited.
Source: Journal of Thrombosis and Haemostasis - May 15, 2013 Category: Hematology Authors: L. V. Andersen, G. Y. H. Lip, J. S. Lindholt, L. Frost Tags: Original Article Source Type: research

Abstract 227: Prescribing Warfarin at Discharge for Heart Failure Patients without Atrial Fibrillation Findings from the Get With The Guidelines-Heart Failure Registry Poster Session II
Conclusions: Approximately 1 in 10 HF patients without AF or other documented indications are prescribed warfarin at discharge, and prescription rates vary widely across hospitals. Further research is needed to understand why anticoagulation is prescribed to patients with HF in the absence of documented indications.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Eapen, Z., Grau-Sepulveda, M., Fonarow, G., Heidenreich, P., Peterson, E., Hernandez, A. Tags: Poster Session II Source Type: research

Quality of Life Assessment in the Randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) Trial of Patients at Risk for Stroke With Nonvalvular Atrial Fibrillation
Conclusions: Patients with nonvalvular AF at risk for stroke treated with left atrial appendage closure have favorable QOL changes at 12 months versus patients treated with warfarin. (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation [WATCHMAN PROTECT]; NCT00129545)
Source: Journal of the American College of Cardiology - April 24, 2013 Category: Cardiology Authors: Oluseun Alli, Shepal Doshi, Saibal Kar, Vivek Reddy, Horst Sievert, Chris Mullin, Vijay Swarup, Brian Whisenant, David Holmes Tags: Heart Rhythm Disorders Source Type: research

Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral Anticoagulation: The ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)
Conclusions: LAA closure with the Watchman device can be safely performed without a warfarin transition, and is a reasonable alternative to consider for patients at high risk for stroke but with contraindications to systemic oral anticoagulation. (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology [ASAP]; NCT00851578)
Source: Journal of the American College of Cardiology - April 12, 2013 Category: Cardiology Authors: Vivek Y. Reddy, Sven Möbius-Winkler, Marc A. Miller, Petr Neuzil, Gerhard Schuler, Jens Wiebe, Peter Sick, Horst Sievert Tags: Atrial Fibrillation Source Type: research

Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?
The objective of this review article is to provide an overview of stroke and bleeding risk assessment in AF. There would be particular emphasis on when, how, and why to use these risk stratification schemes, with a specific focus on the CHADS2 [congestive heart failure, hypertension, age, diabetes, stroke (doubled)], CHA2DS2-VASc [congestive heart failure or left ventricular dysfunction, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65–74 and sex category (female)], and HAS-BLED [hypertension (i.e. uncontrolled blood pressure), abnormal renal/liver function, stroke, bleeding his...
Source: European Heart Journal - April 7, 2013 Category: Cardiology Authors: Lip, G. Y. H. Tags: REVIEWS Source Type: research

Risk-Benefit Profile of Warfarin Versus Aspirin in Patients With Heart Failure and Sinus Rhythm: A Meta-analysis Original Articles
Conclusions— Compared with aspirin, warfarin does not provide benefit in the prevention of stroke and death among patients with heart failure in sinus rhythm, but raises the risk of major bleeding; and therefore its use in these patients is not justified.
Source: Circulation: Heart Failure - March 19, 2013 Category: Cardiology Authors: Lee, M., Saver, J. L., Hong, K.-S., Wu, H.-C., Ovbiagele, B. Tags: Other heart failure, Congestive, Secondary prevention, Coumarins, Anticoagulants, Antiplatelets Original Articles Source Type: research

Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes
Commentary on: Homma S, Thompson JL, Pullicino PM, et al.. WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012;366:1859–69. Context Chronic heart failure (CHF) is common, affecting 1–2% of the population and 10% of people >70 years. Patients with CHF have an increased risk of thromboembolism. Those with atrial fibrillation (AF) should receive warfarin but whether CHF patients with sinus rhythm (SR), whose risk is 1.5–3.5%,1 should receive thromboprophylaxis is unclear. Previous studies, Warfarin/Aspirin Study in Heart failure (warfarin, asp...
Source: Evidence-Based Medicine - March 19, 2013 Category: Internal Medicine Authors: Witte, K. K. A., Jamil, H. A. Tags: Epidemiologic studies, Drugs: cardiovascular system, Stroke, Ischaemic heart disease, Diabetes, Arrhythmias Therapeutics Source Type: research

Efficacy and safety of warfarin vs. antiplatelet therapy in patients with systolic heart failure and sinus rhythm: a systematic review and meta‐analysis of randomized controlled trials
ConclusionsWarfarin as compared with antiplatelet therapy reduces risk of ischemic stroke, does not significantly affect death, myocardial infarction, hospitalization due to heart failure or intracranial hemorrhage and increases major hemorrhage in heart failure patients who are in sinus rhythm.
Source: International Journal of Stroke - March 19, 2013 Category: Neurology Authors: Aaron YL. Liew, John W. Eikelboom, Stuart J. Connolly, Martin O' Donnell, Robert G. Hart Tags: Systematic Review Source Type: research

Screening for Asymptomatic Atrial Fibrillation While Monitoring the Blood Pressure at Home: Trial of Regular Versus Irregular Pulse for Prevention of Stroke (TRIPPS 2.0)
In conclusion, home screening for asymptomatic AF while taking BP measurements can be performed accurately. This can be used to detect new AF, allowing treatment with anticoagulation to reduce the future risk for stroke.
Source: The American Journal of Cardiology - March 18, 2013 Category: Cardiology Authors: Joseph Wiesel, Saji Abraham, Frank C. Messineo Tags: Arrhythmias and Conduction Disturbances Source Type: research

NICE issues final guidance supporting the use of apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation (TA 275)
Source: NICE Area: Evidence > Guidelines NICE has issued final guidance (TA 275) supporting the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with 1 or more risk factors such as:   . prior stroke or transient ischaemic attack . age 75 years or older . hypertension . diabetes mellitus . symptomatic heart failure.   NICE notes that the decision about whether to start treatment with apixaban should be made after an informed discussion between the clinici...
Source: NeLM - Cardiovascular Medicine - February 27, 2013 Category: Cardiology Source Type: news

Upper limb arterial thromboembolism: A systematic review on incidence, risk factors, and prognosis including a meta‐analysis of risk‐modifying drugs
ConclusionsAge, female sex, AF, hypertension, diabetes, myocardial infarction, heart failure and stroke are most common risk factors for thromboembolectomy of the upper limb. The availability of NOAC holds promise in reducing the risk of systemic thromboembolism, but specific data are still limited.© 2013 International Society on Thrombosis and Haemostasis
Source: Journal of Thrombosis and Haemostasis - February 25, 2013 Category: Hematology Authors: L V. Andersen, G Y.H. Lip, J S. Lindholt, L Frost Tags: Original Article ‐ Cardiovascular Medicine Source Type: research